or Try an Advanced Search...

    Technical Analysis for EVO - Evotec SE

    Grade Last Price % Change Price Change
    C 5.30 2.91% 0.15
    EVO closed up 2.91 percent on Wednesday, November 20, 2024, on 46 percent of normal volume. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.
    1 Watcher
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Strong Up Up Up
    Historical EVO trend table...
    Date Alert Name Type % Chg
    Calm After Storm Range Contraction 0.00%
    Wide Bands Range Expansion 0.00%
    Overbought Stochastic Strength 0.00%
    200 DMA Support Bullish 2.91%
    Calm After Storm Range Contraction 2.91%
    Upper Bollinger Band Walk Strength 2.91%
    Wide Bands Range Expansion 2.91%
    Overbought Stochastic Strength 2.91%
    Gapped Down Weakness 2.91%
    Pocket Pivot Bullish Swing Setup -4.50%
    Older End-of-Day Signals for EVO ...

       Recent Intraday Alerts

    Alert Time
    Up 3% about 18 hours ago
    60 Minute Opening Range Breakout about 19 hours ago
    Up 2% about 19 hours ago
    Rose Above Previous Day's High about 23 hours ago
    Up 1% about 23 hours ago
    View Earlier Intraday Alerts

    Free Daily (Stock) Chart Reading

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Analyze My Stocks!
    Configure default chart indicators
    EVO Chart by TradingView
    Basic chart:

    Profile

    Evotec is an industry-leading drug discovery and development partner for the pharmaceutical and biotechnology industry. Evotec's mission is to discover best and first-in-class medicines for a broad range of difficult to treat diseases in collaboration with our partners. Evotec has built a comprehensive suite of fully integrated, next generation technology platforms which it believes will transform the way new drugs are discovered. By leveraging the advanced capabilities of Evotec's integrated platforms, Evotec is able to provide solutions to its partners that enable significant improvements in the quality of new drugs while accelerating the drug discovery process and reducing the high cost of attrition often associated with traditional drug discovery processes.
    Classification
    Sector: Healthcare
    Industry: Drug Manufacturers - Specialty & Generic
    Keywords: Biotechnology Life Sciences Disease Natural Sciences Health Sciences Drugs Medication Drug Discovery

    Is EVO a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 3 bullish, 0 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Nov 20 Halozyme: Fabless Or Not, The Stock Is Now A Steal On Evotec Deal
    Nov 19 Is Evotec SE (EVO) the Best German Stock to Buy Now?
    Nov 19 Evotec plunges amid report it's against Halozyme Therapeutics takeover
    Nov 18 Halozyme Provides Update on Non-Binding Proposal to Combine with Evotec
    Nov 17 Halozyme to Fund Proposed Evotec Takeover in Cash, CEO Says
    Nov 16 Key deals this week: Exxon, Unilever, Cardinal Health, Charter Communications and more
    Nov 15 Large Pharma Partner Halozyme Therapeutics Offers To Acquire Germany-Based Evotec For ~$2 Billion
    Nov 15 Halozyme Submits $2.11 Billion Acquisition Offer For Evotec
    Nov 15 Evotec shares surge 20% on Halozyme's 2 billion euro takeover bid
    Nov 15 Halozyme bids for Evotec; BeiGene gets a new name
    See more EVO news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 11.9999
    52 Week Low 2.85
    Average Volume 213,640
    200-Day Moving Average 5.08
    50-Day Moving Average 3.77
    20-Day Moving Average 4.41
    10-Day Moving Average 4.88
    Average True Range 0.34
    RSI (14) 64.54
    ADX 28.42
    +DI 47.83
    -DI 26.93
    Chandelier Exit (Long, 3 ATRs) 4.62
    Chandelier Exit (Short, 3 ATRs) 4.22
    Upper Bollinger Bands 5.64
    Lower Bollinger Band 3.18
    Percent B (%b) 0.86
    BandWidth 55.71
    MACD Line 0.47
    MACD Signal Line 0.37
    MACD Histogram 0.1003
    Fundamentals Value
    Market Cap 1.88 Billion
    Num Shares 354 Million
    EPS -0.29
    Price-to-Earnings (P/E) Ratio -18.28
    Price-to-Sales 3.26
    Price-to-Book 2.21
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 5.60
    Resistance 3 (R3) 5.59 5.47 5.55
    Resistance 2 (R2) 5.47 5.39 5.48 5.54
    Resistance 1 (R1) 5.39 5.35 5.43 5.40 5.52
    Pivot Point 5.27 5.27 5.29 5.28 5.27
    Support 1 (S1) 5.18 5.19 5.23 5.20 5.08
    Support 2 (S2) 5.07 5.14 5.07 5.06
    Support 3 (S3) 4.98 5.07 5.05
    Support 4 (S4) 5.00